# OX Alpha task: round62_batch_b_context_patents

- Timestamp: 2026-08-22T01:51:41.667955+00:00
- Model: stealth/ox-alpha
- Elapsed: 72.0s
- Finish reason: stop
- Usage: {"prompt_tokens": 4415, "completion_tokens": 2128, "total_tokens": 6543, "cost": 0, "is_byok": false, "prompt_tokens_details": {"cached_tokens": 4352, "cache_write_tokens": 0, "audio_tokens": 0, "video_tokens": 0}, "cost_details": {"upstream_inference_cost": 0, "upstream_inference_prompt_cost": 0, "upstream_inference_completions_cost": 0}, "completion_tokens_details": {"reasoning_tokens": 0, "image_tokens": 0, "audio_tokens": 0}}

## User prompt

```
You are performing a CAPABILITY COLLISION MATRIX analysis for the CTO. This is Round 62, responding to a CEO deep audit that RETRACTED the Round 61 'element (a) confirmed novel' conclusion.

CEO DIRECTIVE: 'The machine must search for capability collisions, not keyword collisions. The fact that nobody used our exact phrase "retrieved-clot physical signature" proves almost nothing. The relevant question is whether someone already has the CAPABILITY.'

This is BATCH B (context patents from prior rounds). Assess each of the 6 patents in this batch against the 8 capabilities below.

THE 8 CAPABILITIES:
1. Intraprocedural clot sensing (any modality — optical, acoustic, force, impedance, ultrasonic, spectroscopic)
2. Clot composition classification (RBC/fibrin/platelet ratio, histology-like)
3. Adherence characterization (clot-vessel adhesion measurement)
4. Physical-property characterization (elasticity, stiffness, modulus, deformation, fracture)
5. Real-time sensing (intra-procedural, sub-second temporal resolution)
6. AI/ML interpretation of clot sensor data
7. Treatment-mode adjustment based on clot sensor data (aspiration state, device selection, pass continuation)
8. Outcome prediction (sICH, 90-day mRS, TICI grade) from clot sensor data

THE 3 PATENTS IN THIS BATCH:

===== PATENT 1: WO2021108783A1 =====
Title: Methods and systems for assessing a vasculature
URL: https://patents.google.com/patent/WO2021108783A1/en
Concern: Re-fetch for capability matrix context — Round 61 description-level review found NO teaching of element (a) but DID teach intra-procedural outcome prediction via API imaging.
Abstract:
Abstract Methods and systems are provided for assessing a vasculature of an individual. In an embodiment of a method, one or more angiographic parametric imaging (API) maps of the vasculature are obtained, wherein each API map of the one or more API maps encodes a hemodynamic parameter. A state of the vasculature is determined using a machine-learning classifier applied to the one or more API maps.

Claims (extracted):
Claims What is claimed is: 1. A method for assessing a vasculature of an individual, comprising: obtaining one or more angiographic parametric imaging (API) maps of the vasculature, wherein each API map of the one or more API maps encodes a hemodynamic parameter; and determining a state of the vasculature using a machine-learning classifier applied to the one or more API maps. 2. The method of claim 1, wherein the machine-learning classifier is a convolutional neural network (CNN). 3. The method of claim 2, wherein the CNN comprises ensemble networks. 4. The method of claim 3, wherein a first network of the ensemble networks is trained using anterior-posterior API maps and a second network of the ensemble networks is trained using lateral API maps, and the state of the vasculature is determined using a combination of results from each network of the ensemble networks. 5. The method of claim 4, wherein the result of each network is weighted by a network coefficient. 6. The method of claim 1, wherein the machine-learning classifier is trained to determine an occlusion state of the vasculature. 7. The method of claim 1, wherein the machine-learning classifier is trained to determine a reperfusion state of the vasculature. 8. The method of claim 1, wherein the hemodynamic parameter is one or more of time to peak (TTP), mean transit time (MTT), time to arrival, peak height (PH), and/or area under the time- density curve (AUC). 9. The method of claim 1, further comprising normalizing the hemodynamic parameter to reduce injection variability. 10. The method of claim 1, further comprising correcting the one or more API maps to account for C-arm position to reduce foreshortening error. 11. The method of claim 1, wherein the received one or more API maps comprise a pre treatment API map and a post-treatment API map. 12. The method of claim 11, further comprising dividing the hemodynamic parameter of the post-treatment API map by the corresponding hemodynamic parameter of the pre-treatment normalized API map. 13. The method of claim 1, wherein the one or more API maps are obtained by generating each API map from a digital subtraction angiography (DSA) image sequence of the vasculature. 14. The method of claim 13, wherein generating each API map comprises temporally cropping the DSA image sequence to only include frames where contrast is shown in the capillary phase. 15. The method of claim 13, wherein generating each API map comprises spatially cropping the DSA image sequence to remove portions outside a region of interest. 16. The method of claim 13, wherein generating each API map comprises extracting a time density curve at each pixel of the DSA image sequence. 17. The method of claim 1, further comprising segmenting the one or more API maps using a CNN. 18. An image processing apparatus, comprising: a memory for storing one or more angiographic parameter imaging (API) maps of a vasculature, wherein each API map of the one or more API maps encodes a hemodynamic parameter; and a processor in electronic communication with the memory, and wherein the process is programmed to determine a state of the vasculature based on the one or more API maps stored in the memory, and wherein the processor determines the state of the vasculature using a machine-learning classifier. 19. The image processing apparatus of claim 18, wherein the processor is further programmed to obtain the one or more API maps and store the one or more API maps in the memory. 20. The image processing apparatus of claim 18, wherein the processor is further programmed to: obtain one or more digital subtraction angiography (DSA) image sequences; generate one or more API maps from the one or more DSA image sequences, wherein each API map corresponds to a DSA image sequence; and store the generated one or more API maps in the memory. 21. The image processing apparatus of claim 20, wherein the processor generates each API map by temporally cropping the DSA image sequence to only

------------------------------------------------------------

===== PATENT 2: US11955237B2 =====
Title: Decision support tool for stroke patients
URL: https://patents.google.com/patent/US11955237B2/en
Concern: Re-fetch for capability matrix context — Viz.ai decision support tool; outcome probability computation but for PRE-PROCEDURAL transfer triage.
Abstract:
Abstract An automated system and method for assisting in decision making for the treatment of stroke patients is provided, and specifically for assisting a physician whether the patient should be administered a drug or transferred to another hospital to undergo an endovascular thrombectomy procedure. A variety of factors are input into the system with limited human intervention and a tool automatically determines the probability of whether the patient will have a better outcome if transferred or not. The factors include clinical factors, imaging factors and time to transfer factors. The tool includes processes for automatically determining several imaging factors, including the determination of clot length, collateral blood flow, the presence of forward blood flow within and around the clot, and the clot permeability. The tool has capability to continuously update the treatment protocol and other output results using current clinical, health system or other relevant information or feedback.

Claims (extracted):
Claims ( 28 ) The invention claimed is: 1. A method to determine that a stroke patient should be transferred from a first treatment facility to a second treatment facility capable of performing endovascular therapy, the method comprising: receiving clinical data for the stroke patient at the first treatment facility; receiving imaging data from one or more imaging modalities for the stroke patient at the first treatment facility and determining an image profile for the stroke patient; inputting the clinical data for the stroke patient and the image profile into a computer device; determining, by the computer device, an estimated transfer time from the first treatment facility to the second treatment facility capable of performing endovascular therapy, an estimated treatment time at the second treatment facility, and a total time to treatment based on the estimated transfer time and the estimated treatment time; determining, by the computer device, a patient assessment profile from the image profile, wherein the patient assessment profile includes an estimate of an amount of brain tissue that may be irreversibly infarcted at the total time to treatment; determining, by the computer device, a probability of an acceptable outcome based on the patient assessment profile and whether the patient is transferred to the second treatment facility capable of performing endovascular therapy; and outputting, by the computer device, based on a plurality of decisive factors, a decision to transfer the patient to the second facility capable of performing endovascular therapy, wherein the computer device is configured to provide automatic decision support by implementing machine learning techniques based on expert physician data, the clinical data, and the imaging data, wherein the plurality of decisive factors include a perfusion threshold value, the patient assessment profile, and an estimated time to reperfusion. 2. The method of claim 1 , wherein determining the probability of an acceptable outcome includes assessment of infarct growth over time. 3. The method of claim 2 , wherein determining the probability of an acceptable outcome includes assessment of any one or more of thrombus morphology, permeability, vascular segmentation, collateral assessment, baseline infarct size, severity and infarct growth over time, and risks for treatment. 4. A computer system programmed to determine that a stroke patient should be transferred from a first treatment facility to a second treatment facility capable of performing endovascular therapy, the computer system programmed to: receive clinical data for the stroke patient at the first treatment facility; receive imaging data from one or more imaging modalities for the stroke patient at the first treatment facility and determine an image profile for the stroke patient; determine an estimated transfer time from the first treatment facility to the second treatment facility capable of performing endovascular therapy, an estimated treatment time at the second treatment facility, and a total time to treatment based on the estimated transfer time and the estimated treatment time; determine a patient assessment profile from the image profile, wherein the patient assessment profile includes an estimate of an amount of brain tissue that may be irreversibly infarcted at the total time to treatment; determine and output a probability of an acceptable outcome based on the patient assessment profile and whether the patient is transferred or not to the second treatment facility capable of performing endovascular therapy; and output, based on a plurality of decisive factors, a decision to transfer the patient to the second facility capable of performing endovascular therapy, to provide automatic decision support by implementing machine learning techniques based on expert physician data, the clinical data, and the imaging data, and wherein the plurality of decisive factors include a perfusion threshold value, the patie

------------------------------------------------------------

===== PATENT 3: US10531883B1 =====
Title: Aspiration thrombectomy system and methods for thrombus removal with aspiration catheter
URL: https://patents.google.com/patent/US10531883B1/en
Concern: Re-fetch for capability matrix context — Aspiration thrombectomy system; pure mechanical.
Abstract:
Abstract A thrombectomy removal system includes a catheter having a distal end and defining a lumen filled with a liquid column having a proximal portion and a distal portion, a vacuum source, a vent liquid source, and a vacuum and vent control system configured to cyclically connect or disconnect the vacuum source and the vent liquid source to change a level of vacuum at the distal end and substantially prevent forward flow. The vacuum source and the vent source are respectively fluidically connected to the vacuum and vent valves. A manifold connects the proximal portion to the vacuum and vent sources through the valves. Control of the valves prevents forward flow of the distal portion out from the distal end during each cycle. Each cycle can have states including vacuum-only, first double-closed, vent-only, and second double-closed. A time of the double-closed states can be no greater than 30 ms.

Claims (extracted):
Claims ( 18 ) What is claimed is: 1. A clot removal system, comprising: a catheter having a distal end and defining a lumen filled with a liquid column having a proximal portion and a distal portion; a controllable vacuum valve; a vacuum source fluidically connected to the vacuum valve; a controllable vent valve having a vent liquid input; a vent fluid source containing a vent liquid and fluidically connected to the vent valve to retain the vent liquid at the vent fluid input; a manifold connected to the catheter, to the vacuum valve, and to the vent valve, the manifold fluidically connecting the proximal portion of the liquid column in the lumen: to the vacuum source through the vacuum valve; and to the vent fluid source through the vent valve; a controller connected to the vacuum valve and the vent valve and configured to selectively open and close the vacuum valve and the vent valve such that: responsive to opening the vacuum valve, the vacuum source is fluidically connected to the liquid column in the lumen; and responsive to opening the vent valve, the vent fluid source is fluidically connected to the liquid column in the lumen, the controller configured to cyclically open and close the vacuum valve and the vent valve to: change a level of vacuum at the distal end; and prevent forward flow of the distal portion out from the distal end during each cycle. 2. The system according to claim 1 , wherein the controller is configured to cyclically open and close the vacuum valve and the vent valve in a repeated cycle comprising a double-closed state in which the vacuum valve is closed and the vent valve is closed. 3. The system according to claim 2 , wherein a time of the double-closed state is no greater than 30 ms. 4. The system according to claim 1 , wherein the controller is configured to cyclically open and close the vacuum valve and the vent valve in a repeated cycle comprising a vent-only state in which the vacuum valve is closed and the vent valve is open. 5. The system according to claim 4 , wherein a time of the vent-only state is no greater than 50 ms. 6. The system according to claim 1 , wherein the controller is configured to selectively open and close the vacuum valve and the vent valve cycle in a repeated cycle comprising: a vacuum-only state in which the vacuum valve is open and the vent valve is closed; a first double-closed state in which the vacuum valve is closed and the vent valve is closed; a vent-only state in which the vacuum valve is closed and the vent valve is open; and a second double-closed state in which the vacuum valve is closed and the vent valve is closed. 7. The system according to claim 6 , wherein a time between an opening of the vent valve and a closing of the vent valve is between approximately 10 ms and approximately 50 ms. 8. The system according to claim 6 , wherein a period of the cycle is between approximately 6 Hz and approximately 16 Hz. 9. The system according to claim 6 , wherein a period of the cycle is between approximately 8 Hz and 12 Hz. 10. The system according to claim 1 , wherein the change in the level of vacuum at the distal end is greater than approximately 15 inHg and no greater than approximately 50 ms. 11. The system according to claim 1 , wherein the change in the level of vacuum at the distal end is greater than approximately 20 inHg and no greater than approximately 30 ms. 12. The system according to claim 1 , wherein the change in the level of vacuum at the distal end is greater than approximately 25 inHg and no greater than approximately 20 ms. 13. The system according to claim 1 , wherein: the lumen has an internal diameter of between approximately 0.038″ and approximately 0.106″; and the controller is configured to cyclically open and close the vacuum valve and the vent valve at a frequency of between 2 and 16 Hz. 14. The system according to claim 1 , wherein: the lumen has an internal diameter of between approximately 0.068″ and approximately 0.088″; and the con

------------------------------------------------------------

YOUR ANALYSIS — for EACH of the 3 patents, produce:

PATENT: <id>
  Title: <title>
  CAPABILITY 1 (intraprocedural clot sensing): YES / NO / PARTIAL — quote language
  CAPABILITY 2 (composition classification): YES / NO / PARTIAL — quote language
  CAPABILITY 3 (adherence characterization): YES / NO / PARTIAL — quote language
  CAPABILITY 4 (physical-property characterization): YES / NO / PARTIAL — quote language
  CAPABILITY 5 (real-time sensing): YES / NO / PARTIAL — quote language
  CAPABILITY 6 (AI/ML interpretation): YES / NO / PARTIAL — quote language
  CAPABILITY 7 (treatment-mode adjustment): YES / NO / PARTIAL — quote language
  CAPABILITY 8 (outcome prediction from clot sensor data): YES / NO / PARTIAL — quote language

SPECIAL NOTE FOR EP3763305A1: The CEO described this patent as "NIR/Raman analysis of clot material; physical properties including adhesion, morphology, permeability, modulus, deformation, fracture; device selection implications." But the fetched title is "System for clot retriever cleaning for reinsertion." Assess: does the description teach NIR/Raman clot analysis? If NOT, state "CEO MIS-CITATION LIKELY" and describe what the patent actually teaches.

CONSTRAINTS:
- Quote ACTUAL claim/description language. Do NOT fabricate.
- If description is truncated, mark INCONCLUSIVE for capabilities that depend on description-only teaching.
- Be adversarial: try to find YES/PARTIAL verdicts. The CTO wants to identify capability collisions.

Target ~1500-2000 words for this batch.

```

## Response (content)

CAPABILITY COLLISION MATRIX — BATCH B (Round 62)
Scope: 3 patents provided. Note: the CEO's special note references EP3763305A1, which is NOT in this batch (this batch contains WO2021108783A1, US11955237B2, US10531883B1). I cannot assess EP3763305A1 without its text; requesting it be added to a subsequent fetch. Flagging now: if EP3763305A1's actual title is "System for clot retriever cleaning for reinsertion," then either the CEO cited the wrong document number or is describing a different family member — CEO MIS-CITATION CANNOT BE CONFIRMED OR DENIED without the document. Do not rely on the CEO's characterization of it until fetched.

=====================================================

PATENT: WO2021108783A1
Title: Methods and systems for assessing a vasculature

CAPABILITY 1 (intraprocedural clot sensing): PARTIAL. It senses vasculature state, not clot material properties. Claim 1: "obtaining one or more angiographic parametric imaging (API) maps of the vasculature... encodes a hemodynamic parameter." Claim 6/7: classifier trained to determine "an occlusion state" / "a reperfusion state." This is hemodynamic imaging of the vessel, not sensing of the clot itself at the device-tissue interface.

CAPABILITY 2 (composition classification): NO. No claim or abstract language addresses RBC/fibrin/platelet content, histology-like classification, or thrombus composition. Hemodynamic parameters listed are TTP, MTT, time to arrival, PH, AUC (claim 8).

CAPABILITY 3 (adherence characterization): NO. No adhesion language anywhere in claims or abstract.

CAPABILITY 4 (physical-property characterization): NO. Encoded quantities are contrast time-density derived; no elasticity/stiffness/modulus/fracture teaching in the provided text.

CAPABILITY 5 (real-time sensing): PARTIAL. API maps are generated intra-procedurally from DSA sequences (claims 13-16), and pre/post treatment maps are compared (claims 11-12), implying use during the procedure. However, temporal resolution is contrast-bolus-limited (seconds per DSA run), not sub-second continuous sensing. INCONCLUSIVE on any description-only real-time loop beyond what claims show.

CAPABILITY 6 (AI/ML interpretation): YES. Claim 1: "determining a state of the vasculature using a machine-learning classifier"; claim 2 CNN; claim 3 ensemble networks; claim 17 segmentation via CNN.

CAPABILITY 7 (treatment-mode adjustment): PARTIAL. Claims 11-12 compare pre- vs post-treatment API maps ("dividing the hemodynamic parameter of the post-treatment API map by... the pre-treatment normalized API map"), which supports procedural decision-making (e.g., reperfusion assessment), but no explicit closed-loop adjustment of aspiration state, device selection, or pass continuation appears in the provided claims. Description may teach more — INCONCLUSIVE on description-only treatment-loop teaching.

CAPABILITY 8 (outcome prediction from clot sensor data): PARTIAL. Round 61 found intra-procedural outcome prediction via API imaging taught at description level; the provided claims support "reperfusion state" determination (claim 7), which is an outcome-relevant output. But the input is angiographic hemodynamics, NOT clot sensor data from a device. Collision is with capability 8's general concept (intra-procedural ML prediction of vascular state), not with clot-sensor-derived prediction specifically.

Strongest attack surface this patent creates: it establishes prior art for "ML classification of intra-procedural angiographic parametric maps to determine reperfusion/occlusion state." Any claim drafted as "ML-based intra-procedural assessment during thrombectomy" collides here unless anchored to direct clot-sensing modality data.

=====================================================

PATENT: US11955237B2
Title: Decision support tool for stroke patients

CAPABILITY 1 (intraprocedural clot sensing): NO / PARTIAL. The system determines imaging-derived clot factors — claim 3: "thrombus morphology, permeability, vascular segmentation, collateral assessment" — but these are computed from pre-procedural imaging modalities at the first facility for transfer triage (claim 1: "determine that a stroke patient should be transferred"). Not intraprocedural device-based sensing.

CAPABILITY 2 (composition classification): PARTIAL. "Thrombus morphology" and "clot permeability" (abstract: "the determination of clot length, collateral blood flow, the presence of forward blood flow within and around the clot, and the clot permeability") are clot-characterization outputs, but morphology/permeability from imaging is not RBC/fibrin/platelet compositional classification. No histology-like ratio teaching in provided text.

CAPABILITY 3 (adherence characterization): NO. No adhesion language in claims or abstract.

CAPABILITY 4 (physical-property characterization): PARTIAL. "Clot permeability" and "presence of forward blood flow within and around the clot" are physical transport properties of the clot, inferred from imaging. Not mechanical properties (modulus/elasticity/fracture).

CAPABILITY 5 (real-time sensing): NO. Operates pre-procedurally at facility 1; the only "continuous" element is updating the protocol with new information (abstract: "capability to continuously update the treatment protocol"), which is decision-update, not sub-second sensing.

CAPABILITY 6 (AI/ML interpretation): YES. Claim 1: "automatic decision support by implementing machine learning techniques based on expert physician data, the clinical data, and the imaging data."

CAPABILITY 7 (treatment-mode adjustment): PARTIAL. It adjusts a treatment DECISION (transfer vs. treat locally, drug vs. EVT) but does not adjust intra-procedural parameters (aspiration state, device selection mid-case, pass continuation). Abstract: "continuously update the treatment protocol."

CAPABILITY 8 (outcome prediction from clot sensor data): PARTIAL. Claim 1: "determining... a probability of an acceptable outcome based on the patient assessment profile"; claim 2: "assessment of infarct growth over time." Outcome probability is predicted, but inputs are clinical + imaging + time factors, not clot sensor data. Strongest collision: ML-based outcome-probability computation using clot-derived imaging features (morphology, permeability). If our invention's outcome-prediction claims are drafted broadly over "clot characteristics -> outcome probability," this patent attacks them; anchoring to intraprocedural device-sensed signals avoids it.

=====================================================

PATENT: US10531883B1
Title: Aspiration thrombectomy system and methods for thrombus removal with aspiration catheter

CAPABILITY 1 (intraprocedural clot sensing): NO. Pure actuation/control. Claims recite valves, vacuum source, vent source, manifold, controller cycling states. No sensor of any modality is claimed or described in the provided text.

CAPABILITY 2 (composition classification): NO. No composition language.

CAPABILITY 3 (adherence characterization): NO. No adhesion language.

CAPABILITY 4 (physical-property characterization): NO. No modulus/elasticity/deformation teaching. The only "physical" quantities are hydraulic: vacuum levels (claims 10-12: ">15 inHg," ">20 inHg," ">25 inHg"), cycle frequencies (claims 8-9: "6 Hz and approximately 16 Hz"), lumen diameters (claim 13: "0.038″ to 0.106″").

CAPABILITY 5 (real-time sensing): NO. Real-time CONTROL exists (sub-30 ms double-closed states, claim 3; 8-12 Hz cycles, claim 9), but there is no sensing input — the cycle is open-loop valve sequencing. Adversarial note: the millisecond-scale control timing demonstrates the field had real-time actuation capability, which weakens any novelty argument resting solely on "sub-second timing" rather than on sensed-parameter feedback.

CAPABILITY 6 (AI/ML interpretation): NO. No ML language in provided text.

CAPABILITY 7 (treatment-mode adjustment): PARTIAL (weak). The controller adjusts vacuum delivery cyclically, but this is fixed-sequence actuation, not adjustment based on measured clot data. No feedback language in provided claims.

CAPABILITY 8 (outcome prediction): NO.

Strategic value of this patent: it is a collision-free reference for all 8 capabilities but is useful defensively — it shows pulsed-vacuum aspiration control was known, so any claim element framed as "cyclically modulating aspiration" alone is dead; novelty must live in the sense-decide-adjust loop.

=====================================================

BATCH SUMMARY
- Capability collisions found: Cap 6 (ML interpretation) — strong collision in both WO2021108783A1 and US11955237B2. Cap 8 (outcome prediction) — partial collision in both, but neither uses device-sensed clot data as input; both use imaging/clinical data. Cap 4 — partial via US11955237B2's imaging-derived clot permeability/morphology.
- Clean capabilities across this batch: Cap 1 (device-based intraprocedural clot sensing), Cap 2 (compositional classification), Cap 3 (adherence), Cap 5 (sub-second device-level sensing), Cap 7 (closed-loop treatment-mode adjustment from sensed clot data).
- Drafting implication: claims should anchor novelty in the sensing modality + closed-loop adjustment chain (Caps 1+5+7), with Caps 6/8 framed as dependent on device-sensed clot signals, not generic imaging features.
- Outstanding item: EP3763305A1 must be fetched before the matrix is complete; the CEO's NIR/Raman characterization is unverified against the actual document. UNKNOWN until fetched.

---

## Reasoning (for audit)

Note: EP3763305A1 not in batch — flag that. Produce matrix for 3 patents.
